Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Strategic Alliance Partners

Early efficacy data in a phase 1 trial of the agent now known as nivolumab were not enough to convince Julie Brahmer, MD, MSc, about the potential of the investigative agent.

Dr. Yarchoan underscores the unique characteristics of fibrolamellar carcinoma, treatment options for these patients, and ongoing research efforts to expand the limited paradigm in this disease.

A new era for patients with newly diagnosed Philadelphia chromosomepositive acute lymphoblastic leukemia may be on the horizon as investigative efforts aimed away from chemotherapy-based regimens prove efficacious.

The discovery of an agent with a unique mechanism of action led investigators to examine sabizabulin, an oral therapy that binds to the colchicine binding site on the microtubule to crosslink α and β tubulin and inhibits microtubule polymerization.

Neoadjuvant treatment with nivolumab combined with chemotherapy led to a significant improvement in pathologic complete response compared with chemotherapy alone in patients with resectable non–small cell lung cancer.

Dr. Levy discusses key research efforts with targeted therapies for patients with lung cancer who harbor NTRK, KRAS, and HER2 aberrations.

Julie R. Brahmer, MD, discusses emerging targeted therapies for patients with lung cancer who harbor EGFR exon 20 insertion mutations.

Although advances in diagnosis and treatment have led to improvements in overall survival for patients with NSCLC, low rates of survival outcomes are present even in those with nonmetastatic disease.

Jerry L​e Pow Spivak, MD, discusses diagnosing essential thrombocythemia.

Kristen A. Marrone, MD, discusses research efforts with osimertinib in EGFR-mutated lung cancer, overcoming resistance to the agent, and optimizing sequential molecular testing.

Nilofer S. Azad, MD, highlights colorectal cancer treatment and how it has entered an era that is both exciting and challenging.

Nilofer S​aba Azad, MD, discusses selecting between regorafenib and TAS-102 in colorectal cancer.

Nilofer S​aba Azad, MD, discusses third-line treatment options for patients with colorectal cancer.

Benjamin P. Levy, MD, discusses the mechanism ​of action of telaglenastat in non–small cell lung cancer.

Nilofer S​aba Azad, MD, discusses future research efforts in colorectal cancer.

Nilofer S​aba Azad, MD, discusses the significance of germline testing in colorectal cancer.

Nilofer S​aba Azad, MD, discusses treatment considerations in right- versus left-sided colorectal cancer.

Jerry L​e Pow Spivak, MD, discusses the prevalence of polycythemia vera.  

Kala Visvanathan, MD, MBBS, MHS, discusses the rationale for ​evaluating lipophilic statins in epithelial ovarian cancer. 

In our exclusive interview, Dr. Levy discusses the challenges of targeting KRAS and highlighted some of the investigational agents directed toward KRAS G12C mutations that have emerged in the NSCLC pipeline.

Treatment approaches are being refined by the primary location of gastroesophageal junction tumors.

Treatment approaches are being refined by the primary location of gastroesophageal junction tumors.

Jean Wright, MD, discusses radiation considerations in breast cancer.

Jean Wright, MD, discusses radiation considerations in breast cancer.

Nivolumab, when administered approximately 4 weeks prior to surgery in patients with Merkel cell carcinoma, was found to be tolerable and to induce pathological complete responses and radiographic tumor regressions.

Jean Wright, MD, discusses proton versus photon radiotherapy in breast cancer.

Amanda Nickles Fader, MD, discusses the rationale for a phase II study and explains how the findings could open the door to other treatment options for women with uterine serous carcinoma.

Emmanuel S. Antonarakis, MBBCh, discusses the efficacy of radium-223 plus sipuleucel-T in patients with bone-metastatic castration-resistant prostate cancer and the next steps for research for this combination.

Amanda Nickles Fader, MD, discusses the utility of trastuzumab plus chemotherapy in HER2-positive uterine serous carcinoma.

Amanda Nickles Fader, MD, discusses the rationale for utilizing HER2/neu as a target in uterine serous carcinoma.